WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

Development of CRISPR-based rapid diagnostic platforms for emerging zoonotic viruses in low-resource settings.

Chiamaka Francisca Igweonu

Researcher, Exact Science Laboratories, US
DOI : https://doi.org/10.55248/gengpi.6.0525.19118

ABSTRACT :

Emerging zoonotic viruses, such as Ebola, Nipah, and SARS-CoV-2, pose an escalating threat to global public health, particularly in low-resource regions where healthcare infrastructure is limited. These viruses, often transmitted from wildlife to humans, can lead to severe outbreaks with high mortality rates and rapid transmission. Early and accurate detection is critical to controlling their spread, but current diagnostic platforms typically require expensive equipment, centralized laboratories, and trained personnel, which are often unavailable in under-resourced areas. CRISPR-based diagnostic technologies have emerged as promising tools for addressing these limitations due to their programmability, specificity, and potential for point-of-care deployment. Platforms such as SHERLOCK and DETECTR leverage Cas13 and Cas12 enzymes to identify viral RNA or DNA with high sensitivity and specificity. Recent advances in lateral flow readouts, lyophilized reagents, and isothermal amplification methods further enhance their field usability. This paper explores the design, development, and deployment of CRISPR-based diagnostic platforms tailored for low-resource settings. Emphasis is placed on optimizing assay stability, reducing cost, enabling rapid detection under ambient conditions, and ensuring ease of use by non-specialist health workers. Case studies involving SARS-CoV-2 and Lassa virus demonstrate the platforms' potential for decentralized outbreak response. By integrating synthetic biology, portable microfluidics, and community-based surveillance systems, CRISPR diagnostics offer a scalable solution for real-time monitoring and containment of zoonotic threats. Their adaptation to low-resource environments is a critical step toward equitable global health security and pandemic preparedness.

Keywords: CRISPR diagnostics, zoonotic viruses, low-resource settings, SHERLOCK, point-of-care detection, outbreak response.

1. INTRODUCTION

1.1 Global Burden of Emerging Zoonotic Viruses

Zoonotic viruses, which are transmitted between animals and humans, have emerged as a critical global health challenge, accounting for over 60% of known infectious diseases and approximately 75% of emerging pathogens in recent decades (1). These viruses often originate in wildlife reservoirs and are transmitted to humans either directly or through intermediate hosts, influenced by anthropogenic activities such as deforestation, urbanization, and intensive animal farming (2). Events like the emergence of Ebola virus in West Africa, the Middle East Respiratory Syndrome (MERS), and the COVID-19 pandemic illustrate the devastating impact of zoonoses on global health, economies, and social systems (3).

The global burden of emerging zoonotic viruses disproportionately affects low- and middle-income countries (LMICs), where health systems are often under-resourced and less capable of managing outbreaks efficiently (4). These regions typically harbor a higher interface between humans and animals, leading to increased spillover risks (5). Furthermore, climate change and global travel have facilitated the rapid spread of zoonotic diseases, expanding their impact beyond localized regions (6). The economic toll of zoonotic outbreaks is significant, with global losses from pandemics estimated to surpass trillions of dollars, including costs associated with healthcare, containment, and economic disruption (7).

Despite advances in surveillance and virology, early detection and containment remain challenging, particularly for novel pathogens. This is compounded by the limited capacity for rapid diagnostics and the fragmented nature of global preparedness systems (8). Addressing this burden requires a One Health approach, integrating human, animal, and environmental health disciplines (9). Global cooperation, sustainable funding, and equitable access to health technologies are critical to mitigating the threats posed by emerging zoonotic viruses (10). These measures will be key in preventing future pandemics and strengthening overall global health resilience.

1.2 Diagnostic Gaps in Resource-Limited Settings

Resource-limited settings face significant diagnostic challenges in the early detection and control of emerging zoonotic diseases, largely due to infrastructural and financial constraints (11). In many LMICs, diagnostic laboratories are scarce, and healthcare workers often lack access to advanced molecular testing platforms, impeding timely confirmation of infections (12). This diagnostic lag contributes to unchecked transmission, delayed interventions, and greater mortality (13).

Rapid diagnostic tools are critical for frontline surveillance and outbreak management. However, many such tools are designed for use in well-equipped laboratories and are unsuitable for deployment in rural or underserved areas (14). Additionally, procurement and supply chain issues often hinder consistent availability of diagnostic reagents and test kits in low-resource environments (15). Even when available, tests may not be validated for novel or region-specific pathogens, further limiting their utility (16).

Another challenge is the integration of laboratory data with public health information systems. In many regions, weak health information infrastructure makes it difficult to track and respond to outbreaks in real-time (17). Moreover, a lack of training among local health professionals impairs the interpretation and communication of diagnostic results, affecting the quality of care (18).

Innovative approaches such as mobile diagnostics, point-of-care testing, and digital health platforms offer promise but are yet to achieve widespread implementation due to cost and logistical barriers (19). Bridging these diagnostic gaps requires targeted investments, international collaboration, and local capacity-building initiatives that emphasize sustainable and context-appropriate solutions for vulnerable populations (20).

1.3 Research Objectives and Article Structure

This article aims to critically examine the global burden of emerging zoonotic viruses, with a specific focus on diagnostic gaps in resource-limited settings. The overarching objective is to synthesize current knowledge on the epidemiology of zoonotic spillovers, assess diagnostic readiness across diverse health systems, and propose targeted strategies for improving early detection and response capabilities (21). By drawing from a multidisciplinary lens, the study seeks to highlight the intersection of epidemiology, diagnostics, public health policy, and equity in pandemic preparedness (22).

The article is structured into several key sections. Following this introduction, Section 2 delves into the drivers of zoonotic virus emergence, including ecological, environmental, and socioeconomic factors that facilitate spillover events (23). Section 3 outlines current diagnostic technologies available for zoonotic disease detection, their limitations in low-resource settings, and the promise of emerging innovations such as CRISPR-based assays and mobile diagnostics (24). Section 4 provides case studies of recent outbreaks, including Ebola, Nipah, and SARS-CoV-2, analyzing diagnostic bottlenecks and lessons learned (25).

Section 5 presents a strategic framework for improving diagnostic readiness, including recommendations on infrastructure development, workforce training, international collaboration, and policy reform (26). Finally, Section 6 offers a conclusion that reiterates the importance of investing in diagnostics as a core component of global health security (27).

This structured analysis intends to guide researchers, public health stakeholders, and policymakers in understanding and addressing critical diagnostic challenges, especially in regions that remain disproportionately burdened by zoonotic outbreaks (28). Through evidence-based recommendations, the article aspires to contribute meaningfully to future pandemic preparedness efforts.

2. CRISPR TECHNOLOGY: FROM GENOME EDITING TO DIAGNOSTICS

2.1 Overview of CRISPR-Cas Systems

The CRISPR-Cas (Clustered Regularly Interspaced Short Palindromic Repeats–CRISPR-associated) systems, initially discovered as part of bacterial immune defenses, have evolved into a powerful toolset for genetic engineering and molecular diagnostics (5). At the core of these systems are CRISPR-associated (Cas) proteins, which are guided by RNA molecules to recognize and cleave specific nucleic acid sequences. Originally employed by bacteria to fend off viral infections, CRISPR-Cas systems have been repurposed for precise genome editing, gene regulation, and nucleic acid detection in biomedical sciences (6).

Different types of CRISPR-Cas systems have been identified, with Types II, V, and VI showing the most utility in diagnostics due to their ability to be programmed for specific target sequences (7). Cas9, the most well-known variant, introduces double-stranded DNA breaks, while Cas12 and Cas13 possess collateral cleavage activity, making them ideal for use in detection platforms where signal amplification is crucial (8). Cas12 targets single-stranded DNA, whereas Cas13 targets single-stranded RNA, both triggering nonspecific cleavage of surrounding nucleic acids once the target is recognized (9).

The versatility of CRISPR-Cas systems lies in their programmability and adaptability. They can be easily reconfigured to detect new pathogens by altering the guide RNA sequence, making them highly responsive to evolving public health threats (10). Furthermore, the integration of these systems into lateral flow assays and fluorescence-based formats has enabled their deployment in field-ready, point-of-care diagnostics (11).

Recent developments such as SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) and DETECTR (DNA Endonuclease Targeted CRISPR Trans Reporter) platforms exemplify the diagnostic potential of CRISPR-Cas tools (12). These platforms combine isothermal amplification with CRISPR-based detection, allowing for rapid and sensitive identification of viral RNA or DNA without the need for complex instrumentation (13). As such, CRISPR-Cas systems are now at the forefront of next-generation diagnostics, promising scalable, affordable, and accessible testing solutions globally, particularly for emerging and re-emerging zoonotic diseases (14).

2.2 Mechanism of CRISPR-Based Detection (Cas12, Cas13, SHERLOCK, DETECTR)

CRISPR-based diagnostic platforms leverage the programmable nature of Cas enzymes to detect nucleic acids with high specificity and sensitivity. Two major enzymes, Cas12 and Cas13, are integral to these systems, with each targeting different types of nucleic acid sequences (15). Cas12 recognizes double-stranded DNA targets, while Cas13 targets RNA sequences. Upon binding their respective targets, both enzymes exhibit "collateral cleavage" activity, where they indiscriminately cut nearby reporter molecules, producing detectable signals such as fluorescence or visual bands on lateral flow strips (16).

The SHERLOCK platform, based on Cas13a, utilizes an isothermal amplification step known as recombinase polymerase amplification (RPA) or loopmediated isothermal amplification (LAMP) to generate RNA from a target DNA sequence. Cas13a then binds to this RNA, and upon activation, cleaves a fluorescently labeled RNA reporter (17). This system has been shown to detect viral RNA from pathogens like Zika and SARS-CoV-2 with femtomolar sensitivity, enabling rapid detection within an hour (18).

Conversely, DETECTR utilizes Cas12a in conjunction with an RPA step to detect DNA targets. When Cas12a binds its target, it cleaves a single-stranded DNA reporter molecule, resulting in a signal that can be visualized via fluorescence or lateral flow assay formats (19). DETECTR has been particularly effective in identifying human papillomavirus (HPV) and SARS-CoV-2, demonstrating its robustness and field applicability (20).

Cas12 and Cas13 enzymes are highly specific, reducing the likelihood of false positives, a common issue in conventional diagnostic tools (21). Their sensitivity is further enhanced by the collateral cleavage activity, which serves as a built-in signal amplification mechanism, eliminating the need for complex lab equipment (22). Additionally, these systems can be rapidly adapted for new targets by altering the guide RNA sequences, enabling a swift response to emerging pathogens (23).

These platforms are often integrated with low-cost detection technologies such as paper-based sensors and smartphone readers, making them suitable for use in decentralized and resource-limited settings (24). Their robustness, combined with rapid turnaround times and high accuracy, positions CRISPR-based diagnostics as transformative tools in the global fight against infectious diseases (25).

2.3 Comparative Advantages over Traditional Diagnostics

Compared to conventional diagnostic methods such as polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA), CRISPR-based diagnostics offer several compelling advantages (26). The foremost benefit lies in their simplicity and rapid turnaround. Traditional PCR requires thermal cycling and laboratory infrastructure, whereas CRISPR systems operate under isothermal conditions and can yield results in less than an hour (27).

Sensitivity is another notable strength. The collateral cleavage mechanism of Cas12 and Cas13 enzymes amplifies detection signals naturally, allowing for detection of minute quantities of nucleic acids (28). In contrast, PCR, while sensitive, often requires multiple processing steps and risk of contamination, which can impact accuracy and delay results (29). CRISPR diagnostics also exhibit high specificity due to the precision of guide RNA targeting, which minimizes off-target effects and false positives commonly encountered with antibody-based tests like ELISA (30).

Moreover, CRISPR-based tools are inherently scalable and can be adapted quickly in response to emerging pathogens by simply redesigning the guide RNA sequence. This modularity offers a clear edge over traditional assays, which may take months to develop and validate for new targets (31). Their compatibility with portable and low-tech devices makes them suitable for deployment in the field or at the point of care, a feat rarely achievable with conventional diagnostics (32).

In terms of cost and accessibility, CRISPR diagnostics are increasingly viewed as economically feasible alternatives, especially for resource-limited settings. They represent a paradigm shift in diagnostics, merging molecular precision with practical applicability to improve global health surveillance (33).



Figure 1: Schematic diagram of CRISPR-Cas12 and Cas13 diagnostic mechanisms

Table 1: Comparison between CRISPR, RT-PCR, and Antigen-Based Diagnostics

Parameter	CRISPR-Based Diagnostics	RT-PCR (Reverse Transcription PCR)	Antigen-Based Tests
Target	Viral RNA or DNA (sequence-specific via guide RNA)	Viral RNA (converted to cDNA for amplification)	Viral proteins (e.g., nucleocapsid or spike proteins)
Sensitivity	Very high (femtomolar levels)	High (can detect low viral loads)	Moderate to low (requires high viral loads)
Specificity	Very high (depends on guide RNA accuracy)	High (requires specific primers/probes)	Moderate (may cross-react with other pathogens)
Time-to-Result	30–60 minutes	2–6 hours (lab dependent)	15–30 minutes
Equipment Needs	Minimal (can be portable or lateral flow-based)	Requires thermal cycler and lab setup	Minimal (strip-based, portable)
Cold Chain Dependency	Moderate (improving with lyophilized reagents)	High (enzymes and reagents require refrigeration)	Low (most kits are stable at room temperature)
Ease of Use	Moderate (requires some training, increasingly simplified)	Low (requires skilled personnel and laboratory setup)	High (designed for point-of-care and home use)
Cost per Test	Low to moderate (scalable with local production)	High (equipment, reagents, and labor-intensive)	Low (widely available and mass-produced)
Mutation Detection	High (can be reprogrammed quickly for variants)	Moderate (primer mismatch can reduce sensitivity)	Low (may miss new variants with protein changes)
Field Deployment	High potential (especially with smartphone integration)	Limited (requires stable infrastructure)	Very high (widely used in community testing)

3. ZOONOTIC VIRUS LANDSCAPE AND PRIORITY PATHOGENS

3.1 Virological and Transmission Characteristics of Zoonotic Pathogens

Zoonotic pathogens possess a wide array of virological characteristics that influence their ability to infect humans and spread within populations. These viruses often originate in wild animal reservoirs and gain entry into human hosts through direct contact, ingestion, or via intermediate vectors such as mosquitoes, bats, or rodents (11). Once a successful spillover event occurs, human-to-human transmission may be facilitated through respiratory droplets, body fluids, or contaminated surfaces, depending on the virus's structure and stability outside the host (12).

Many zoonotic viruses exhibit high mutation rates, particularly RNA viruses, enabling rapid adaptation to new hosts and environments (13). This mutability enhances their potential for virulence, immune evasion, and transmissibility. For instance, coronaviruses and filoviruses possess complex surface proteins that enable efficient cell entry by binding to host receptors like ACE2 or NPC1, which are expressed across a variety of tissues (14). These characteristics often correlate with multisystem involvement, severe disease presentations, and high case-fatality rates (15).

Additionally, zoonotic viruses often demonstrate long incubation periods and asymptomatic shedding, complicating outbreak containment efforts (16). This was evident in diseases like SARS and Ebola, where early symptoms mimic common illnesses, delaying diagnosis and isolation (17). Environmental persistence is another key feature; viruses like Ebola and Marburg can remain infectious on surfaces for extended periods under the right conditions, elevating transmission risks in healthcare and community settings (18).

The zoonotic transmission chain is shaped by ecological disruptions such as habitat loss, wildlife trade, and climate variability, which increase human-animal interfaces (19). Understanding these virological traits is essential for designing effective diagnostics, vaccines, and control measures, particularly in settings with heightened vulnerability to spillover events (20). Future preparedness relies on deepening knowledge of these viral dynamics to mitigate cross-species transmission and subsequent outbreaks.

3.2 Key Emerging Viruses: Nipah, Zika, Ebola, Marburg, SARS-CoV-2

Several zoonotic viruses have recently garnered international attention due to their outbreak potential and severe health outcomes. The Nipah virus, first identified in Malaysia in 1998, is a paramyxovirus transmitted from fruit bats to humans either directly or through infected animals such as pigs (21). Human-to-human transmission also occurs, particularly in Bangladesh and India, where outbreaks have caused encephalitis and respiratory failure with mortality rates exceeding 70% (22).

Zika virus, a flavivirus transmitted by Aedes mosquitoes, caused a global public health emergency in 2016 due to its link with microcephaly in newborns and Guillain-Barré syndrome in adults (23). Although symptoms are typically mild or absent, the virus's ability to cross the placental barrier underscores its pathogenic potential. Zika spread rapidly across the Americas, aided by the widespread distribution of its vector and global travel (24).

Ebola virus, a filovirus, emerged in Central Africa in 1976 and has since caused multiple deadly outbreaks, most notably the West African epidemic from 2014 to 2016 (25). Transmission occurs through direct contact with infected bodily fluids, often in healthcare or funeral settings. Despite the availability of vaccines and experimental therapies, Ebola outbreaks persist due to limited surveillance, public distrust, and fragile health systems (26).

Marburg virus, another filovirus closely related to Ebola, has caused sporadic outbreaks with high case-fatality rates of up to 88%. Originating in African fruit bats, it spreads through close contact with infected individuals or animals (27). The disease presents with hemorrhagic fever and multisystem failure, often complicating diagnosis and timely intervention (28).

SARS-CoV-2, the causative agent of COVID-19, emerged in late 2019 from a suspected animal source, potentially a bat or intermediate host, in China (29). The virus spreads primarily via respiratory droplets and aerosols, with a high basic reproduction number (R0), making it exceptionally contagious. Its clinical spectrum ranges from asymptomatic infection to severe respiratory distress and death (30). Variants of concern with mutations in the spike protein have continued to drive waves of transmission, challenging vaccine efficacy and diagnostic accuracy (31).

Collectively, these viruses highlight the diverse transmission pathways, clinical outcomes, and surveillance demands associated with emerging zoonoses. Each pathogen underscores the urgent need for agile, cross-border public health strategies and diagnostic platforms that can adapt to evolving threats (32).

3.3 Diagnostic Challenges Across WHO Blueprint Priority Viruses

The World Health Organization (WHO) has identified a list of Blueprint priority pathogens—such as Ebola, Marburg, Nipah, SARS-CoV-2, and Zika—due to their epidemic potential and lack of adequate countermeasures (33). One of the primary challenges in managing these viruses is the timely and accurate diagnosis, particularly in low-resource settings where outbreaks often originate (34). Early symptoms of many Blueprint viruses are nonspecific, including fever, headache, and fatigue, which complicates clinical diagnosis and can lead to delays in isolation and treatment (35).

Molecular diagnostics like RT-PCR remain the gold standard but require laboratory infrastructure, trained personnel, and reliable electricity, all of which are scarce in outbreak-prone regions (36). During the 2014–2016 Ebola epidemic, for instance, diagnosis was often delayed by days due to the need for sample transport to central laboratories, worsening transmission risks (37). Additionally, the window of viral detection varies between pathogens; while Ebola and Marburg may require detection in blood, Zika virus may be best detected in urine or saliva, necessitating different protocols and sample types (38).

Cross-reactivity is another concern, especially for flaviviruses like Zika and dengue, which share genetic similarities and can result in false positives using conventional serological assays (39). Moreover, mutation rates in RNA viruses can compromise the sensitivity of PCR assays if primer sequences are not regularly updated, as observed with SARS-CoV-2 variants (40).

Logistical constraints, such as cold-chain requirements for reagents and stockouts of test kits, further hamper large-scale screening during outbreaks (41). Despite efforts to deploy point-of-care solutions, many remain in pilot phases or are cost-prohibitive for routine use in endemic regions (42). Therefore, strengthening laboratory networks, standardizing diagnostic algorithms, and integrating novel technologies like CRISPR-based diagnostics are crucial for addressing these persistent gaps in pathogen detection (43).



Figure 2: Global zoonotic hotspots with overlay of diagnostic response gaps

Table 2: WHO R&D Blueprint Pathogens and Current Field Diagnostics Status

Pathogen	WHO Priority Status	Current Field Diagnostics Available	Challenges in Field Use
Ebola Virus	High	RT-PCR, GeneXpert, rapid antigen tests	Cold chain dependency, biosafety level 4 (BSL-4) handling
Marburg Virus	High	RT-PCR, antigen detection (limited)	High biosafety requirements, few validated POC tests
Nipah Virus	High	RT-PCR (central lab), CRISPR (pilot stage)	Lack of commercial rapid tests, decentralized deployment limited
Lassa Fever Virus	High	RT-PCR, lateral flow immunoassays (under development)	Cross-reactivity, low sensitivity in early infection
Zika Virus	Medium	RT-PCR, CRISPR (pilot), antibody ELISA	Cross-reactivity with dengue, limited RNA stability
Crimean-Congo Hemorrhagic Fever (CCHF)	High	RT-PCR, ELISA (limited)	Geographic restriction, few validated field kits
Middle East Respiratory Syndrome (MERS-CoV)	High	RT-PCR (central lab only)	Asymptomatic carriage, under-detection in field settings
Severe Acute Respiratory Syndrome (SARS-CoV-1)	High	RT-PCR (archived), no active field use	Obsolete diagnostics; risk remains due to lab leakage
COVID-19 (SARS-CoV-2)	Emergency	RT-PCR, CRISPR, rapid antigen, LAMP	Variant adaptation, affordability in LMICs
Rift Valley Fever Virus	High	RT-PCR, ELISA, lateral flow prototypes	Lack of scale-up, low field validation
Unknown "Disease X"	Placeholder	Not applicable	Need for modular, rapidly deployable diagnostics

4. DESIGN PRINCIPLES FOR CRISPR DIAGNOSTICS IN LOW-RESOURCE SETTINGS

4.1 Key Parameters: Sensitivity, Specificity, Time-to-Result, Portability

In evaluating the effectiveness of diagnostic platforms, particularly for zoonotic diseases, four key parameters are essential: sensitivity, specificity, time-to-result, and portability. Sensitivity reflects a test's ability to detect true positives, which is crucial during the early stages of infection when viral loads are low (15). CRISPR-based systems such as SHERLOCK and DETECTR have demonstrated femtomolar sensitivity, rivaling or even exceeding that of standard RT-PCR (16). High sensitivity ensures minimal false negatives, reducing the risk of undetected community transmission.

Specificity, on the other hand, refers to a test's ability to avoid false positives by accurately identifying the target pathogen without cross-reacting with non-target organisms (17). This is particularly important in regions where multiple co-circulating pathogens may exhibit similar clinical symptoms. For instance, CRISPR systems utilize guide RNAs to bind to unique viral sequences, ensuring precise pathogen identification even among genetically similar viruses (18).

Time-to-result is critical in outbreak settings where rapid decision-making is vital. Traditional diagnostics like PCR may take several hours to deliver results, whereas CRISPR-based assays can provide reliable outcomes in under an hour (19). This speed enables immediate isolation, contact tracing, and treatment initiation, which are crucial for containment.

Portability plays a pivotal role in resource-limited settings. The development of compact, battery-operated diagnostic devices that do not rely on complex laboratory infrastructure significantly enhances access in rural and underserved areas (20). Platforms integrated into paper-based lateral flow assays or handheld fluorescence detectors have shown great promise in this regard (21). By combining these four performance indicators, CRISPR diagnostics present a formidable alternative to traditional methods, especially in pandemic-prone regions with limited diagnostic capabilities (22). These attributes collectively enable more effective disease monitoring, response, and control in real-world scenarios.

4.2 Sample Preparation Strategies Without Cold Chain Dependency

Sample preparation remains a critical bottleneck in deploying diagnostics in field and remote settings, particularly due to reliance on cold chain logistics to maintain sample integrity (23). Traditional protocols for nucleic acid extraction typically require cold storage, centrifugation, and complex reagents that are not readily available in low-resource environments (24). To circumvent these challenges, several innovations have emerged that eliminate cold chain dependency while preserving diagnostic accuracy.

One such innovation is the use of lyophilized reagents, which remain stable at ambient temperatures and can be reconstituted with minimal resources (25). These reagents include enzymes for amplification and detection steps in CRISPR diagnostics, significantly improving their shelf-life and transportability. Additionally, researchers have developed room-temperature stable buffers that allow for direct lysis of biological samples, such as saliva or blood, without the need for RNA purification kits or refrigeration (26).

Heat-based inactivation methods, which use portable heaters or even body heat to denature viral particles, have also been integrated into point-of-care workflows to simplify sample preparation (27). This approach not only reduces biosafety risks but also expedites the diagnostic process by removing additional steps (28). Paper-based extraction techniques are another emerging strategy, using filter paper to trap viral RNA or DNA, which can then be directly used in downstream reactions (29).

Furthermore, magnetic bead-based protocols have been adapted for use without cold chain or electricity, relying on manual shaking and simple magnets for nucleic acid isolation (30). These low-tech approaches are proving particularly useful for CRISPR systems deployed in community-based surveillance programs (31). As diagnostic technologies move toward decentralization, innovations in cold-chain-independent sample preparation are vital to ensuring scalability and sustainability of testing programs worldwide (32).

4.3 Integration with Lateral Flow and Smartphone-Based Readers

The integration of CRISPR-based diagnostics with lateral flow assays (LFAs) and smartphone-based readers represents a critical advancement in making molecular diagnostics accessible at the point of care. LFAs, widely known for their simplicity and affordability, use capillary action to transport fluid samples along a test strip embedded with specific antibodies or nucleic acid probes (33). When combined with CRISPR systems like Cas12 or Cas13, these tests become highly sensitive and specific, offering rapid and visual detection through colorimetric signals (34).

For instance, DETECTR integrates Cas12a with a lateral flow strip that includes a reporter molecule labeled with both biotin and fluorescein. Upon target recognition and activation, Cas12a cleaves the reporter, allowing a visible test band to form on the strip (35). This simple visualization mechanism requires no specialized training, making it suitable for community health workers and lay users (36). These CRISPR-LFA combinations have demonstrated successful detection of SARS-CoV-2, HPV, and other high-priority pathogens in under an hour, underlining their practical utility in outbreak scenarios (37).

The evolution of smartphone-based readers further enhances the diagnostic power of these platforms. Smartphones, equipped with high-resolution cameras, advanced image processing, and connectivity capabilities, serve as portable readers to interpret and quantify test results from LFAs or fluorescence-based reactions (38). Custom apps can capture images of the test strip or fluorescence readout, analyze signal intensity, and relay the data to healthcare providers or surveillance systems in real time (39).

This real-time data transfer capability is especially important for tracking emerging outbreaks in decentralized regions. In addition, GPS tagging and cloud integration allow for geospatial mapping of cases, enhancing public health response and resource allocation (40). Smartphone integration also supports the use of augmented reality (AR) features and machine learning algorithms to improve result interpretation and reduce operator bias (41).

Another advantage is the democratization of diagnostics. Individuals can conduct tests at home and transmit results to healthcare professionals, supporting remote consultations and reducing healthcare system burden (42). This model was notably piloted during the COVID-19 pandemic, where at-home CRISPR tests combined with smartphone readers were evaluated for mass testing initiatives (43). Furthermore, researchers have developed 3D-printed attachments and fluorescence detection hardware that transform regular smartphones into full diagnostic tools, further reducing cost barriers (44).

Beyond infectious disease detection, these platforms are also being adapted for monitoring antimicrobial resistance, cancer biomarkers, and environmental pathogens, widening their impact across health sectors (45). However, widespread adoption requires regulatory validation, robust user training, and equitable access to digital infrastructure (46). As these integrated systems continue to evolve, they offer an unprecedented opportunity to reimagine decentralized healthcare delivery, especially in areas where laboratory testing has traditionally been out of reach (47).



Figure 3: Workflow of sample-to-answer CRISPR diagnostic test optimized for field use

Table 3: Field Performance Metrics for Selected CRISPR-Based Test Prototypes

Test Name / Platform	Target Pathogen	Cas Enzyme	Time-to-Result	Sensitivity (LoD)	Specificity (%)	Deployment Context
DETECTR	SARS-CoV-2	Cas12a	30–45 minutes	~10 copies/µL	>95%	Mobile labs, community clinics (USA, Senegal)
SHERLOCK	Zika, Dengue	Cas13a	~60 minutes	~2 aM (attomolar) RNA	~98%	Field testing in Brazil, Thailand
FELUDA	SARS-CoV-2	FnCas9	~60 minutes	~10–100 copies/µL	96–98%	Rural diagnostics (India)
CARMEN-Cas13	Multiplex respiratory viruses	Cas13a	~90 minutes	10^2–10^3 copies/µL (varies)	>90%	Pilot studies, high-throughput screening
VAULT	SARS-CoV-2 variants	Cas12a/Cas13a	45–60 minutes	5–50 copies/µL	>95%	Point-of-care variant monitoring (USA)
ENHANCE	Lassa, Ebola (experimental)	Cas12a	30–60 minutes	~100 copies/µL	~94%	Lab-to-field validation (Nigeria)
CRISPR-Nipah Rapid	Nipah virus (pilot)	Cas12b	~40 minutes	~10^2 copies/µL	~95%	Community surveillance (Bangladesh)

Legend:

- *LoD* = Limit of Detection
- *Cas12a/13a/12b/FnCas9* = CRISPR-associated enzymes used for nucleic acid targeting
- *Deployment Context* indicates where or how the platform has been piloted or validated.

5. CASE STUDIES: PILOT DEPLOYMENTS OF CRISPR DIAGNOSTICS

5.1 CRISPR Deployment for SARS-CoV-2 in Senegal and India

The COVID-19 pandemic catalyzed the global deployment of CRISPR-based diagnostics, with notable early implementations in Senegal and India. In Senegal, the Institut Pasteur de Dakar collaborated with international partners to develop and validate a CRISPR-based test that could be locally produced and deployed across rural health facilities (19). The test leveraged the DETECTR platform, integrating Cas12a enzymes with a lateral flow strip for easy interpretation without electricity or refrigeration (20). This setup was tailored to the realities of sub-Saharan Africa, where laboratory capacity is limited and transportation of clinical samples can be logistically challenging (21).

The affordability and simplicity of the DETECTR platform enabled widespread use in both urban centers and rural clinics, facilitating early detection and isolation measures. The test achieved high concordance with RT-PCR in detecting SARS-CoV-2 RNA, with results available in under an hour (22). Its deployment helped bridge critical diagnostic gaps during the early months of the pandemic when supply chains for PCR reagents were disrupted (23).

In India, the Council of Scientific and Industrial Research (CSIR) introduced a CRISPR-based diagnostic known as FELUDA (FnCas9 Editor Linked Uniform Detection Assay), developed at the CSIR-Institute of Genomics and Integrative Biology (24). Unlike Cas12 or Cas13 platforms, FELUDA employed Cas9 fused with a reporter molecule, offering a high-fidelity method for SARS-CoV-2 detection with visual outputs via paper strips (25). It was approved for emergency use by Indian regulatory authorities and manufactured locally at scale (26).

FELUDA was rolled out in mobile testing vans and rural health camps, enabling community testing in areas with limited healthcare infrastructure (27). The assay's rapid time-to-result, low cost, and adaptability to smartphone-based readers made it particularly effective in reaching underserved populations (28). These country-specific deployments underscore how CRISPR diagnostics can be successfully localized to meet regional needs and health system constraints while maintaining scientific rigor and diagnostic accuracy (29). They also exemplify the feasibility of decentralized molecular diagnostics for pandemic response, especially in lower-middle-income countries facing acute testing shortages (30).

5.2 Detection of Dengue and Zika in Rural South America

The endemicity of mosquito-borne diseases like dengue and Zika in rural South America has prompted the exploration of novel diagnostic tools to enhance surveillance and timely clinical response. CRISPR-based platforms, with their sensitivity and portability, have been piloted in countries such as Brazil, Colombia, and Peru to support early detection and public health interventions (31). These efforts often target remote regions where vector control programs are hindered by poor infrastructure and lack of laboratory services (32).

A CRISPR-Cas13-based diagnostic developed in Brazil used SHERLOCK technology to differentiate between dengue and Zika viruses, which share significant genomic homology and overlapping clinical presentations (33). Traditional serological tests frequently yield false positives due to cross-reactivity, especially during co-circulating outbreaks, making molecular differentiation critical (34). The CRISPR assay was tailored to detect viral RNA directly from saliva samples, eliminating the need for venous blood draws, and delivering results within 45 minutes using a lateral flow reader (35).

In Colombia, pilot programs deployed mobile testing stations equipped with solar-powered CRISPR diagnostic kits, enabling village-level disease surveillance during seasonal dengue spikes (36). The local health workers, trained in less than two days, were able to conduct tests using simplified protocols and smartphones to record results and transmit data to centralized surveillance systems (37). These real-time updates allowed health authorities to map outbreak clusters and coordinate insecticide spraying and community awareness efforts more efficiently (38).

Zika virus detection was also incorporated into antenatal care programs in rural Peru, where pregnant women were tested using a CRISPR diagnostic integrated into routine health visits (39). The ability to detect Zika early in gestation was vital in preventing congenital complications and informing clinical follow-up (40). Here, the test's paper-strip design proved ideal for midwives and community health volunteers, many of whom operated in resource-scarce jungle areas (41).

These South American deployments highlight CRISPR's transformative potential in arboviral diagnostics, offering specificity and sensitivity that outpaces conventional methods while adapting to local epidemiological and infrastructural realities (42). They serve as a template for expanding molecular diagnostics beyond urban hospitals into the heart of at-risk communities (43).

5.3 Community-Based Nipah Surveillance Using CRISPR Kits

Nipah virus, a highly lethal zoonotic pathogen endemic to parts of South and Southeast Asia, presents significant challenges for early detection and outbreak containment. Traditional diagnostic methods for Nipah, including PCR and ELISA, are centralized and require high biosafety-level facilities, delaying field responses in endemic zones such as Kerala (India), Bangladesh, and northern Malaysia (44). Community-based CRISPR diagnostic kits are emerging as a promising solution to address this diagnostic bottleneck.

In Kerala, following repeated Nipah outbreaks, public health authorities partnered with biotech startups and academic institutions to pilot Cas12a-based CRISPR assays capable of detecting Nipah virus RNA from oropharyngeal swabs within 30 to 45 minutes (45). These assays were distributed to mobile health units stationed near outbreak-prone districts, enabling frontline detection during seasonal bat migration periods (46). The test was designed to operate on minimal power, using portable fluorescence detectors, and incorporated lyophilized reagents that could be stored without refrigeration (47).

In Bangladesh, community health workers were trained to use CRISPR diagnostic strips to monitor symptomatic individuals during active surveillance programs in villages near bat roosts (48). Surveillance was integrated with education campaigns that taught residents to avoid consuming raw date palm sap, a known transmission pathway for Nipah virus (49). Test results, recorded via smartphone apps, were geotagged and shared in real-time with central epidemiological teams (50).

The ability to detect Nipah virus outside of laboratory environments significantly improved response time, reducing delays in patient referral and isolation. Moreover, early detection in animals and symptomatic contacts helped preempt larger outbreaks, underscoring the value of decentralized diagnostics in zoonotic surveillance (51). In Malaysia, veterinary field units also employed CRISPR kits to monitor livestock in bat-contact areas, offering a One Health approach that linked animal and human surveillance systems (52).

These deployments demonstrate that CRISPR technology, when embedded into community health structures, can function as a frontline defense against deadly pathogens like Nipah (53). By empowering local health actors with accurate and rapid diagnostics, these programs not only curb transmission but also build trust and resilience in public health systems (54). The success of these models offers a replicable framework for integrating CRISPR-based surveillance in high-risk zones worldwide (55).



Figure 4: Field test results and adoption challenges by region

6. IMPLEMENTATION CHALLENGES AND BIOSAFETY CONSIDERATIONS

6.1 Regulatory Hurdles and Local Validation Requirements

The rapid evolution of CRISPR-based diagnostics presents unique regulatory challenges, particularly in low- and middle-income countries (LMICs) where oversight frameworks for novel diagnostics may be underdeveloped. Unlike traditional diagnostics such as PCR or ELISA, CRISPR systems are not universally categorized within existing regulatory frameworks, making standardized approval processes difficult to implement across jurisdictions (23). National regulatory authorities often require rigorous local validation studies before granting emergency use authorization or full-scale deployment, even when global efficacy data exists (24).

One major hurdle lies in the lack of harmonized global standards for evaluating CRISPR diagnostics. In many countries, including those with high disease burdens, there is limited technical capacity to assess the analytical sensitivity, specificity, and reproducibility of these novel platforms (25). This situation slows the approval pipeline and discourages local manufacturers or distributors from investing in CRISPR diagnostic products, especially when timelines are uncertain (26). For example, during the COVID-19 pandemic, delays in national approvals for CRISPR-based tests in parts of Africa and Asia impeded their use despite strong supporting data (27).

Furthermore, country-specific validation requirements often demand in-country trials using local clinical samples and demographics, which may not always align with the data used for global approvals (28). This discrepancy creates duplication of effort and financial burdens for smaller biotech companies seeking market entry in resource-limited settings (29). The requirement for WHO prequalification also presents an additional layer of regulatory navigation, particularly for diagnostics intended for procurement by global health organizations (30).

To overcome these regulatory barriers, collaborative initiatives are needed. Regional regulatory harmonization bodies, such as the African Medicines Agency (AMA) and the South Asian Association for Regional Cooperation (SAARC), could streamline approvals and promote mutual recognition of test performance data (31). Joint evaluations and fast-track emergency use authorizations, modeled after FDA's Emergency Use Authorization pathway, would accelerate access in high-burden areas (32). Ultimately, building local regulatory expertise through partnerships and technical assistance will be essential to ensure timely, safe, and equitable access to CRISPR diagnostics in the face of emerging health threats (33).

6.2 False Positives/Negatives and Cas Enzyme Storage Stability

Despite their promise, CRISPR-based diagnostics face technical limitations, particularly concerning test accuracy and enzyme stability under field conditions. One of the key concerns is the occurrence of false positives and false negatives, which can compromise public trust and undermine containment efforts. False positives may arise from off-target cleavage by the Cas enzymes or contamination of reagents during sample handling, particularly in decentralized environments (34). Conversely, false negatives can result from insufficient target amplification, mutations in the viral genome that affect guide RNA binding, or enzymatic degradation during storage and transport (35).

Mitigating these inaccuracies requires stringent quality control at both the reagent production and end-user levels. CRISPR diagnostic platforms must incorporate internal positive and negative controls within each test to ensure validity, especially when used by non-specialist operators in the field (36). Advances in bioinformatics are also being used to enhance guide RNA design, improving specificity and minimizing off-target cleavage (37). However, widespread genomic surveillance is required to ensure guide RNAs are regularly updated to reflect circulating viral variants (38).

Another critical issue is the cold-chain dependency of CRISPR reagents, particularly the Cas enzymes, which are sensitive to temperature fluctuations. Enzyme degradation can drastically reduce test sensitivity and reliability if reagents are exposed to heat or are stored improperly (39). To address this, researchers have developed lyophilized (freeze-dried) versions of Cas enzymes that remain stable at ambient temperatures for extended periods, eliminating the need for refrigeration (40). These lyophilized reagents can be activated with simple rehydration steps and have shown comparable performance to cold-stored formulations (41).

Field validation studies from Bangladesh and Kenya have confirmed the feasibility of using lyophilized CRISPR reagents in community surveillance programs, even during hot and humid seasons (42). Nonetheless, widespread adoption of these thermostable formats requires regulatory approval and production scale-up (43). Ensuring robust storage and handling protocols across the diagnostic supply chain is essential to maintain the accuracy and reliability of CRISPR diagnostics in low-resource and decentralized environments (44).

6.3 Biosafety, Training, and Decentralized Testing Protocols

The successful implementation of CRISPR-based diagnostics in community and low-resource settings hinges on effective biosafety practices, personnel training, and the establishment of standardized testing protocols for decentralized environments. Unlike centralized laboratories, where testing is conducted under controlled biosafety conditions, decentralized deployments pose additional risks related to contamination, misinterpretation, and inadequate infection control (45). Ensuring biosafety in such settings begins with the use of closed-system assays, which minimize exposure to biological samples and reagents during testing (46).

Community-based programs have adopted simplified biosafety protocols that include single-use consumables, sealed lateral flow strips, and pre-packaged reagent kits to prevent operator exposure and environmental contamination (47). In many cases, the entire diagnostic process—from sample collection to result interpretation—is conducted in less than one hour, reducing the time samples remain active and thus minimizing biosafety risks (48).

Equally critical is the training of frontline personnel. While CRISPR tests are designed for ease of use, training is still essential to ensure proper sample handling, test execution, and result documentation (49). Training programs developed in India, Peru, and Uganda demonstrated that health workers with minimal laboratory experience could competently perform CRISPR-based diagnostics following short, module-based instruction and supervision (50). Training materials often include pictorial guides, video tutorials, and app-based checklists to accommodate low-literacy environments (51).

The establishment of decentralized testing protocols is also vital for standardization. These protocols include guidance on patient eligibility, sample types, result thresholds, data logging, and reporting pathways (52). Smartphone integration plays a key role in enabling secure, real-time data transmission from remote settings to central public health databases, supporting timely outbreak responses (53). Moreover, decentralized protocols facilitate the integration of CRISPR testing into routine care, such as antenatal visits or school health programs, expanding their reach (54).

To ensure long-term sustainability, governments and NGOs must invest in training-of-trainer models, supply chain support, and community engagement strategies that promote local ownership and trust in decentralized diagnostics (55). These efforts will be instrumental in embedding CRISPR technologies into health systems where they are most urgently needed.

7. SYSTEMS INTEGRATION AND DATA INFRASTRUCTURE IN LOW-RESOURCE SETTINGS

7.1 Real-Time Data Transmission and Mobile App Interfaces

The integration of real-time data transmission and mobile app interfaces into CRISPR-based diagnostics significantly enhances their impact on disease surveillance and outbreak control. In low-resource and decentralized environments, where laboratory reporting systems are often delayed or non-existent, mobile apps offer a direct and immediate pathway for capturing, interpreting, and sharing diagnostic data (29). CRISPR tests combined with smartphone interfaces allow users to scan lateral flow results or fluorescence readouts, which are then automatically analyzed and uploaded to secure cloud platforms (30).

These interfaces can incorporate user authentication, GPS tagging, timestamping, and automated reporting functions, enabling structured data collection that is both traceable and analyzable (31). In pilot programs across India, Kenya, and Brazil, mobile applications connected to CRISPR diagnostic kits facilitated real-time geospatial mapping of test results, allowing public health officials to identify emerging hotspots and track pathogen spread dynamically (32). This rapid data aggregation significantly reduces the latency between case identification and public health action, enabling faster contact tracing, isolation protocols, and community-level interventions (33).

Furthermore, these apps can be customized to provide multilingual interfaces, visual instructions for test procedures, and automated error-checking algorithms, making them accessible even to lay users or community health workers with limited formal training (34). Some platforms have incorporated features like cloud dashboards for health officials and offline capabilities for areas with intermittent connectivity (35). These features ensure that diagnostic efforts are not siloed but integrated into broader epidemiological intelligence systems.

Overall, real-time data transmission through mobile interfaces amplifies the utility of CRISPR diagnostics by embedding them in digital health ecosystems. This synergy enhances responsiveness, accountability, and data-driven decision-making in outbreak contexts, especially in regions where rapid diagnostic feedback loops were previously unfeasible (36).

7.2 Linking Results to Public Health Systems and Outbreak Alerts

To maximize the public health value of CRISPR diagnostics, test results must be effectively linked to national surveillance frameworks and early warning systems. In many endemic regions, fragmented health systems and lack of interoperable platforms have historically delayed outbreak alerts and hindered coordinated responses (37). CRISPR-enabled diagnostic tools, when embedded with automated reporting capabilities, offer an opportunity to modernize and streamline these systems (38).

By integrating mobile health (mHealth) technologies with CRISPR diagnostics, real-time data can feed directly into existing disease surveillance networks such as the Integrated Disease Surveillance and Response (IDSR) platform in Africa or India's Integrated Health Information Platform (IHIP) (39). This linkage ensures that each confirmed case, especially for notifiable zoonotic diseases like Ebola, Nipah, or Zika, triggers predefined alerts and response workflows across local and national levels (40). Early detection data from community testing can thereby inform stockpiling of medical supplies, resource deployment, and risk communication strategies (41).

Application programming interfaces (APIs) are being developed to allow CRISPR diagnostic apps to sync with health ministry databases, electronic health records, and global platforms like WHO's Epidemic Intelligence from Open Sources (EIOS) (42). These integrations provide a common operational picture across ministries, healthcare facilities, and humanitarian agencies working in outbreak zones (43). For instance, in Uganda and Bangladesh, CRISPR diagnostics linked with national dashboards helped map asymptomatic carriers during surveillance campaigns, influencing vector control and containment protocols (44).

The immediacy of linking results to public health databases also strengthens transparency and accountability, allowing real-time public access to outbreak maps and data visualizations. This accessibility fosters public trust, community participation, and evidence-based policymaking during high-stakes health emergencies (45).

7.3 Ethical Considerations and Data Sovereignty

The deployment of CRISPR-based diagnostics and associated digital infrastructure raises critical ethical considerations, particularly around data privacy, consent, and sovereignty. As real-time health data is collected through mobile apps and cloud systems, questions emerge about who owns the data, how it is stored, and who has access (46). In many cases, CRISPR test users may be from rural or marginalized communities with limited understanding of digital data implications, increasing the risk of uninformed consent or misuse of personal health information (47).

Data sovereignty is a pressing issue, especially in LMICs where diagnostic data may be processed or stored on servers controlled by foreign developers or donors. This dynamic risks replicating exploitative models where local health data is used for global research or commercial purposes without equitable benefit sharing (48). Ethical frameworks must prioritize community ownership, requiring that data generated from CRISPR diagnostics be governed according to national policies and local values (49).

Consent processes must also be adapted to low-literacy and culturally diverse settings, incorporating visual aids and community dialogues to ensure comprehension (50). Digital consent should not be limited to a checkbox in an app but embedded into broader health education efforts that explain the implications of sharing health data, especially in outbreak settings where stigma may be a concern (51). Furthermore, anonymization and data encryption must be standard features of all CRISPR diagnostic platforms to prevent breaches and unauthorized profiling (52).

International ethical standards, such as those outlined in the Declaration of Helsinki and WHO's guidelines on digital health, must be localized and enforced (53). Ultimately, ethical implementation of CRISPR diagnostics will depend on strong local governance, inclusive data policies, and community engagement mechanisms that uphold human rights while advancing disease detection and control (54).

Figure 5: Flowchart showing diagnostic data integration with national surveillance systems

8. STRATEGIC ROADMAP FOR SCALABLE ADOPTION

8.1 Local Manufacturing and Cost Reduction Strategies

For CRISPR-based diagnostics to achieve widespread adoption in low- and middle-income countries (LMICs), cost-effective manufacturing and localization are essential. Relying on imported kits drives up expenses and introduces delays, especially during health emergencies when global supply chains are strained. Local manufacturing offers a sustainable alternative that can reduce costs, ensure timely availability, and promote self-sufficiency in diagnostic innovation (33). Countries like India, South Africa, and Brazil have demonstrated this through public-private partnerships that enable domestic production of reagents, lateral flow strips, and Cas enzymes (34).

One cost-saving strategy involves developing open-source CRISPR platforms with standardized protocols and reagents that can be manufactured using regional bioscience infrastructure (35). For example, lyophilized Cas proteins and buffer components can be produced in bulk using local fermentation facilities, significantly lowering per-test costs (36). Additionally, reusable equipment such as portable fluorescence readers or 3D-printed components can minimize one-time hardware expenses (37). Governments can further support affordability by subsidizing critical input materials or waiving import duties for components not yet produced locally (38).

Technology transfer agreements are another vital tool. Collaborations with research institutions in the Global North can help local companies acquire production know-how, intellectual property rights, and quality control protocols (39). The Indian FELUDA project and the African Cas13 initiative illustrate how South-South and North-South partnerships can scale diagnostics without relying solely on high-cost commercial platforms (40). Engaging local biotechnology startups and university spin-offs fosters innovation ecosystems that cater to regional health priorities while creating jobs and infrastructure (41).

Scaling manufacturing must also address regulatory compliance and consistent quality assurance. Local production facilities should be supported to meet international standards like ISO 13485 and Good Manufacturing Practices (GMP), enabling them to participate in global procurement networks (42). Overall, investing in domestic manufacturing capacity is a strategic imperative for long-term affordability, resilience, and equitable access to CRISPR diagnostics across LMICs (43).

8.2 Capacity Building, Training, and Stakeholder Engagement

Building local capacity for CRISPR diagnostics goes beyond manufacturing—it also involves cultivating human capital, institutional readiness, and multisectoral partnerships. Capacity-building efforts should target laboratory technicians, community health workers, biomedical engineers, and regulatory staff to ensure that each stakeholder can play an informed role in the diagnostic value chain (44). Short courses, online certifications, and in-person training modules tailored to local contexts have been shown to be effective in countries like Kenya, Vietnam, and Peru (45).

Training programs must address not only test operation but also biosafety, data handling, maintenance of diagnostic tools, and communication of results (46). For frontline health workers, pictorial guides and mobile-based instructional videos can improve retention and usability in rural settings (47). Additionally, mentorship programs between universities and rural clinics can strengthen ongoing support and foster a network of decentralized diagnostic champions (48). These efforts are particularly important in areas where high staff turnover or limited formal education can impede the sustainability of diagnostic programs (49).

Stakeholder engagement is another cornerstone of success. Governments, NGOs, community leaders, private sector partners, and patient advocacy groups should be involved from the outset to ensure buy-in and culturally appropriate implementation (50). In Bangladesh and the Democratic Republic of Congo, participatory workshops helped adapt CRISPR diagnostics to local health beliefs, leading to higher community trust and usage (51). Engaging policymakers also ensures that diagnostics are integrated into national disease control strategies and health insurance schemes (52).

Collaborations with ministries of health and regional disease control centers can also align diagnostic deployment with national surveillance goals (53). For example, linking CRISPR training efforts to existing laboratory strengthening programs ensures coherence with broader health system capacity-building (54). A well-informed stakeholder ecosystem is essential to drive innovation uptake, address local needs, and ensure accountability at all levels (55). Investing in human and institutional capacity ultimately maximizes the public health return on CRISPR diagnostics.

8.3 Policy Recommendations and Global Health Governance Role

To unlock the full potential of CRISPR diagnostics, targeted policy interventions are necessary at national, regional, and global levels. First, governments should embed CRISPR diagnostics into their national health policies and essential diagnostics lists to enable procurement through public health channels (56). This formal inclusion ensures sustainable financing, particularly for community-based surveillance of priority zoonotic diseases (47). It also opens the door for integration with universal health coverage schemes, enhancing access among underserved populations (38).

Second, international health organizations must play a more assertive role in validating and coordinating CRISPR technologies across countries. The World Health Organization (WHO) and regional bodies like the Africa Centres for Disease Control and Prevention (Africa CDC) can establish standardized evaluation frameworks and offer prequalification pathways to streamline regulatory approvals (29). This role is especially vital for harmonizing performance data, ensuring cross-border interoperability, and supporting countries without strong regulatory infrastructure (40).

Third, global financing mechanisms such as the Global Fund, Gavi, and the Coalition for Epidemic Preparedness Innovations (CEPI) should expand their mandates to include CRISPR diagnostics. Supporting local production, workforce training, and digital integration must become key funding pillars to prepare for future pandemics (21). These platforms can also serve as vehicles for equitable technology transfer agreements and pooled procurement initiatives that ensure fair pricing and distribution (52).

Finally, policy must safeguard equitable access through intellectual property reforms and open-access licensing. Global health governance frameworks must promote collective ownership of diagnostic innovations, especially those developed with public funds or during global health emergencies (33). Strategic alignment of CRISPR diagnostics with health diplomacy and public policy will be essential to ensuring that their benefits are widely shared and sustainably implemented (44).

9. CONCLUSION

9.1 Summary of Innovation Trajectory and Key Takeaways

The evolution of CRISPR diagnostics represents a significant milestone in the convergence of molecular biology, digital health, and public health innovation. Initially conceptualized as a bacterial defense mechanism, CRISPR technology has been repurposed into a powerful diagnostic tool with the potential to revolutionize how infectious diseases are detected, monitored, and managed. Over the past decade, the innovation trajectory has moved swiftly from proof-of-concept experiments in research labs to real-world applications deployed during global health crises such as COVID-19.

One of the most transformative aspects of CRISPR diagnostics lies in its modularity and adaptability. With platforms like SHERLOCK, DETECTR, and FELUDA, the core CRISPR components can be easily reprogrammed to detect different pathogens by changing only the guide RNA sequence. This flexibility allows rapid reconfiguration in response to new or mutating pathogens, making it a valuable tool for outbreak preparedness. Unlike traditional diagnostics that depend on centralized laboratories and costly infrastructure, CRISPR tests offer a low-cost, point-of-care solution that performs reliably in both urban hospitals and remote village clinics.

Key takeaways from this innovation journey include the importance of user-centered design, particularly when deploying diagnostics in low-resource settings. Simplicity, portability, and fast time-to-result emerged as critical success factors. Equally important is the role of digital integration—pairing diagnostics with smartphone apps and real-time reporting systems has amplified their public health utility. Moreover, the success of CRISPR deployment during SARS-CoV-2 and other viral outbreaks underscores the need for cross-sector collaboration. Partnerships between academia, public health agencies, private biotech firms, and local communities were essential in moving from lab bench to bedside.

The CRISPR diagnostic revolution is not just a scientific achievement but a public health breakthrough. It demonstrates that sophisticated molecular tools can be democratized and tailored to the needs of frontline health workers and underserved populations. As global health systems continue to face emerging infectious threats, the agility and accessibility of CRISPR diagnostics will play an increasingly central role in disease detection and control, closing longstanding gaps in surveillance and care.

9.2 Long-Term Impact on Pandemic Preparedness and Rural Health

The long-term implications of CRISPR diagnostics on pandemic preparedness and rural health systems are profound. Traditional diagnostics, while effective in controlled laboratory environments, often falter in rural and underserved settings due to infrastructure constraints, logistical delays, and high costs. CRISPR-based diagnostics address many of these limitations by providing rapid, reliable, and low-resource testing options. Their ability to detect pathogens at the point of care significantly reduces the delay between symptom onset and diagnosis, which is critical in curbing the spread of infectious diseases during outbreaks.

For pandemic preparedness, CRISPR tools offer the advantage of rapid adaptation. As new pathogens emerge, updated guide RNAs can be synthesized and incorporated into existing test platforms within days. This contrasts sharply with conventional systems that often require months of development and validation. The speed of this response capability allows for early containment measures, targeted isolation, and faster public health responses.

In rural areas, where healthcare infrastructure may be minimal, CRISPR diagnostics facilitate decentralized testing. Health workers equipped with portable kits can screen patients in remote locations without needing access to central laboratories. This decentralization improves early detection and empowers local health systems to take preventive measures before outbreaks escalate. In the long term, widespread availability of such tools can shift the paradigm from reactive outbreak response to proactive disease monitoring.

Furthermore, these innovations support data equity. Through integration with mobile devices and digital health platforms, CRISPR diagnostics help generate valuable epidemiological data from regions traditionally underrepresented in global health surveillance. This inclusion fosters more accurate mapping of disease burden and improves resource allocation. Ultimately, CRISPR diagnostics enhance the resilience of public health systems by equipping even the most remote communities with tools that were once confined to advanced laboratories.

9.3 Final Reflections on Democratizing CRISPR Diagnostics

The journey toward democratizing CRISPR diagnostics is as much about equity and empowerment as it is about technology. In a world where access to healthcare remains deeply unequal, the ability to decentralize molecular diagnostics through affordable, portable, and user-friendly platforms has the potential to transform global health landscapes. CRISPR tools bring scientific precision to the doorstep of communities that have long been excluded from the benefits of advanced diagnostics.

At the heart of this democratization is the principle of accessibility—not only in terms of cost but also usability and relevance. CRISPR diagnostics can be adapted to detect pathogens that are regionally significant yet globally neglected. This localized customization fosters health sovereignty and enables countries to prioritize their unique public health challenges rather than relying on imported solutions that may not fit their epidemiological realities.

Equally critical is community participation. The success of CRISPR diagnostics in various settings has demonstrated the value of engaging local stakeholders in design, deployment, and feedback loops. When community health workers, educators, and patients are involved in the diagnostic process, trust is built, and uptake increases. This inclusive approach transforms diagnostics from a top-down intervention into a community-driven solution.

Looking forward, the goal is to embed CRISPR diagnostics within routine healthcare and public health infrastructure. This means supporting policies that fund local production, building training pipelines, and ensuring digital infrastructure reaches the last mile. It also means fostering international cooperation to promote open science, data sharing, and technology transfer.

The democratization of CRISPR diagnostics is not an endpoint—it is the beginning of a broader shift toward health equity. It reimagines diagnostics as a right rather than a privilege, ensuring that all communities, regardless of geography or income, can participate in and benefit from scientific innovation.

REFERENCE :

1. Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, et al. Global trends in emerging infectious diseases. *Nature*. 2008;451(7181):990–3.
2. Karesh WB, Dobson A, Lloyd-Smith JO, Lubroth J, Dixon MA, Bennett M, et al. Ecology of zoonoses: natural and unnatural histories. *Lancet*. 2012;380(9857):1936–45.
3. Morens DM, Fauci AS. Emerging pandemic diseases: how we got to COVID-19. *Cell*. 2020;182(5):1077–92.
4. Tambo E, Adetunde OT, Olalubi OA, Asangbeh SL, Quaglio G. Re-emerging Ebola haemorrhagic fever in West Africa: a global health concern and preventive strategies. *J Infect Dev Ctries*. 2014;8(06):647–53.
5. Bhutta ZA, Sommerfeld J, Lassi ZS, Salam RA, Das JK. Global burden, distribution, and interventions for infectious diseases of poverty. *Infect Dis Poverty*. 2014;3:21.
6. Kilpatrick AM, Randolph SE. Drivers, dynamics, and control of emerging vector-borne zoonotic diseases. *Lancet*. 2012;380(9857):1946–55.
7. Cyranoski D. Infectious disease: the long road to zero Ebola cases. *Nature*. 2015;517(7534):545–8.
8. Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K. Potential for global spread of a novel coronavirus from China. *J Travel Med*. 2020;27(2):taaa011.
9. Mackenzie JS, Jeggo M. The One Health approach—why is it so important? *Trop Med Infect Dis*. 2019;4(2):88.
10. Wilkinson E. The impact of pandemic preparedness programs. *Bull World Health Organ*. 2020;98(8):530–2.
11. Morse SS, Mazet JA, Woolhouse M, Parrish CR, Carroll D, Karesh WB, et al. Prediction and prevention of the next pandemic zoonosis. *Lancet*. 2012;380(9857):1956–65.
12. Pulliam JR, Epstein JH, Dushoff J, Rahman SA, Bunning M, Jamaluddin AA, et al. Agricultural intensification, priming for persistence, and the emergence of Nipah virus. *Proc Natl Acad Sci USA*. 2012;109(10):3535–9.
13. Holmes EC. The evolution and emergence of RNA viruses. Oxford: Oxford University Press; 2009.
14. Letko M, Seifert SN, Olival KJ, Plowright RK, Munster VJ. Bat-borne virus diversity, spillover and emergence. *Nat Rev Microbiol*. 2020;18(8):461–71.
15. Wang L-F, Anderson DE. Viruses in bats and potential spillover to animals and humans. *Curr Opin Virol*. 2019;34:79–89.

16. Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. *N Engl J Med*. 2003;348(20):1953–66.
17. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. *Lancet*. 2011;377(9768):849–62.
18. Kuhn JH, Becker S, Ebihara H, Geisbert TW, Johnson KM, Kawaoka Y, et al. Proposal for a revised taxonomy of the family Filoviridae. *Arch Virol*. 2010;155(12):2083–103.
19. Gootenberg JS, Abudayyeh OO, Kellner MJ, Joung J, Collins JJ, Zhang F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. *Science*. 2018;360(6387):439–44.
20. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science*. 2018;360(6387):436–9.
21. Broughton JP, Deng X, Yu G, Fasching CL, Servellita V, Singh J, et al. CRISPR–Cas12-based detection of SARS-CoV-2. *Nat Biotechnol*. 2020;38(7):870–4.
22. Joung J, Ladha A, Saito M, Segel M, Bruneau R, Huang M, et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. *N Engl J Med*. 2020;383(15):1492–4.
23. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, et al. Field-deployable viral diagnostics using CRISPR-Cas13. *Science*. 2018;360(6387):444–8.
24. Azhar M, Phan T, Singhvi N, Panneerselvam P, Suresh A, Gangakhedkar R, et al. A CRISPR-based FELUDA test detects SARS-CoV-2 variants. *Nat Biomed Eng*. 2021;5:1–4.
25. Ekundayo F, Ikumapayi OJ. Leadership practices in overseeing data engineers developing compliant, high-performance REST APIs in regulated financial technology environments. *Int J Comput Appl Technol Res*. 2022;11(12):566–577. doi:10.7753/IJCATR1112.1021.
26. Kellner MJ, Koob JG, Gootenberg JS, Abudayyeh OO, Zhang F. SHERLOCK: nucleic acid detection with CRISPR nucleases. *Nat Protoc*. 2019;14(10):2986–3012.
27. Arizti-Sanz J, Freije CA, Stanton AC, Boehm CK, Petros BA, Siddiqui S, et al. Streamlined inactivation, amplification, and Cas13-based detection of SARS-CoV-2. *Nat Commun*. 2020;11(1):5921.
28. Emmanuel Oluwagbade and Oluwole Raphael Odumbo. Building resilient healthcare distribution networks: Adapting to crises, securing supplies and improving scalability. *Int J Sci Res Arch.* 2025;14(01):1579–98. Available from: https://doi.org/10.30574/ijsra.2025.14.1.0265
29. Temitope Abiodun Ogunkoya. Transforming hospital-acquired infection control through interdisciplinary, evidence-based nursing bundles in U.S. acute care. *Int J Eng Technol Res Manag* [Internet]. 2022 Dec ;6(12). Available from: https://doi.org/10.5281/zenodo.15533974
30. Fowosere Sodiq, Esechie Courage Obofoni, Namboozo Sarah, Anwansedo Friday. The role of artificial intelligence in green supply chain management. *International Journal of Latest Technology in Engineering Management & Applied Science*. 2025;14(2):33. doi: 10.51583/ijltemas.2025.14020033
31. Li SY, Cheng QX, Liu JK, Nie XQ, Zhao GP, Wang J. CRISPR-Cas12a-assisted nucleic acid detection. *Cell Discov*. 2018;4:20.
32. Emmanuel Ochuko Ejedegba (2024) 'INTEGRATED STRATEGIES FOR ENHANCING GLOBAL FOOD SECURITY AMID SHIFTING ENERGY TRANSITION CHALLENGES', International Journal of Engineering Technology Research & Management (ijetrm), 08(12). doi: 10.5281/zenodo.14502251,
33. Enemosah A, Chukwunweike J. Next-Generation SCADA Architectures for Enhanced Field Automation and Real-Time Remote Control in Oil and Gas Fields. Int J Comput Appl Technol Res. 2022;11(12):514–29. doi:10.7753/IJCATR1112.1018.
34. Patchsung M, Jantarug K, Pattama A, Aphicho K, Suraritdechachai S, Meesawat P, et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. *Nat Biomed Eng*. 2020;4(12):1140–9.
35. Metsky HC, Freije CA, Kosoko-Thoroddsen TS, Sabeti PC, Myhrvold C. CRISPR-based COVID-19 surveillance in developing countries. *Trends Microbiol*. 2021;29(1):2–4.
36. Debanjan M, Rohit P, Vasudevan J, Rajnish P. Use of smartphone-assisted CRISPR diagnostics for resource-limited settings. *BMC Infect Dis*. 2021;21(1):721.
37. Ramachandran A, Huyke DA, Sharma E, Sahoo MK, Huang C, Banaei N, et al. Electric field–driven microfluidics for rapid CRISPR-based diagnostics. *Proc Natl Acad Sci USA*. 2020;117(47):29518–25.
38. Adegoke Sunday Oladimeji, Obunadike Thankgod Chiamaka**.** Global tariff shocks and U.S. agriculture: causal machine learning approaches to competitiveness and market share forecasting. *Int J Res Publ Rev*. 2025 Apr;6(4):16173–16188. Available from: https://doi.org/10.55248/gengpi.6.0425.16109
39. Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical and economic effects of widespread rapid testing to decrease SARS-CoV-2 transmission. *Ann Intern Med*. 2021;174(6):803–10.
40. Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell*. 2021;184(9):2372–83.e9.
41. Ejedegba Emmanuel. Innovative solutions for food security and energy transition through sustainable fertilizer production techniques. *World Journal of Advanced Research and Reviews*. 2024 Dec;24(3):1679–1695. Available from: https://doi.org/10.30574/wjarr.2024.24.3.3877
42. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. *Nature*. 2013;496(7446):504–7.
43. Musso D, Gubler DJ. Zika virus. *Clin Microbiol Rev*. 2016;29(3):487–524.
44. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. *Science*. 1988;239(4839):476–81.
45. Martinot AJ, Abbott RK, Arora P, Bangaru S, Baric RS, Bauer K, et al. A practical framework for global access to COVID-19 diagnostics. *Lancet Glob Health*. 2021;9(8):e1046–52.

46. Ekundayo F. Strategies for managing data engineering teams to build scalable, secure REST APIs for real-time FinTech applications. Int J Eng Technol Res Manag. 2023 Aug;7(8):130. Available from: https://doi.org/10.5281/zenodo.15486520
47. Dzinamarira T, Nachipo B, Phiri B, Musuka G. COVID-19: The role of decentralized testing in rural areas of low-income countries. *Lancet Glob Health*. 2020;8(12):e1454.
48. Bonney JH, Soghoian DZ, Nyarko EO, Huang D, Timm J, Armstrong D, et al. Evaluation of field-deployable CRISPR diagnostic tests in Ghana. *Am J Trop Med Hyg*. 2022;106(5):1245–9.
49. Raymond Antwi Boakye, George Gyamfi, Cindy Osei Agyemang. DEVELOPING REAL-TIME SECURITY ANALYTICS FOR EHR LOGS USING INTELLIGENT BEHAVIORAL AND ACCESS PATTERN ANALYSIS. International Journal of Engineering Technology Research & Management (IJETRM). 2023Jan21;07(01):144–62.
50. Ahmed, Md Saikat Jannat, Syeda Tanim, Sakhawat Hussain. ARTIFICIAL INTELLIGENCE IN PUBLIC PROJECT MANAGEMENT: BOOSTING ECONOMIC OUTCOMES THROUGH TECHNOLOGICAL INNOVATION. International journal of applied engineering and technology (London) (2024). 6. 47-63.
51. Rybak M, Zimmer M. Training frontline health workers in point-of-care diagnostics: impact on response time and case detection. *J Glob Health*. 2021;11:03014.
52. Hanna D, Das S, Obasi I, Mweemba L, Tembo B, Kim H. Community-led bio-surveillance and CRISPR: Lessons from field programs in Africa. *Glob Health Sci Pract*. 2022;10(2):223–30.
53. Ugwueze VU, Chukwunweike JN. Continuous integration and deployment strategies for streamlined DevOps in software engineering and application delivery. Int J Comput Appl Technol Res. 2024;14(1):1–24. doi:10.7753/IJCATR1401.1001.
54. Paltiel AD, Walensky RP. Treating and tracking: A dual imperative for diagnostics in epidemic response. *Health Aff*. 2021;40(3):455–61.
55. Kelley M, Ferrand RA, Muraya K, Chigudu S, Molyneux S. An appeal for practical ethics in pandemic response. *Lancet*. 2020;395(10239):1694–6.
56. WHO. Ethics and governance of artificial intelligence for health: WHO guidance. Geneva: World Health Organization; 2021.